Envestnet Asset Management
FATE icon

Envestnet Asset Management’s Fate Therapeutics FATE Stock Holding History

Envestnet Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,136
Closed -$384K – 3985
2022
Q3 		$384K Buy
17,136
+8,287
+94% +$239K ﹤0.01% 3201
2022
Q2 		$219K Buy
8,849
+115
+1% +$3.17K ﹤0.01% 3533
2022
Q1 		$339K Buy
8,734
+1,457
+20% +$56.4K ﹤0.01% 3377
2021
Q4 		$426K Buy
+7,277
New +$412K ﹤0.01% 3171

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Envestnet Asset Management's FATE Position: Q4 2022 in Review

Envestnet Asset Management sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 17,136 shares — an estimated $384K sold.

Envestnet Asset Management first reported a position in FATE in Q4 2021 and held it in 4 quarters. The position peaked at $426K in Q4 2021. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Envestnet Asset Management reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Envestnet Asset Management sold 17,136 Fate Therapeutics shares in Q4 2022, an estimated $384K.
  • Envestnet Asset Management first reported a position in Fate Therapeutics in Q4 2021 and held it in 4 quarters.
  • Envestnet Asset Management's Fate Therapeutics position peaked at $426K in Q4 2021.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Envestnet Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.